These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy. Schmidt JJ; Strunk AK; David S; Bode-Böger SM; Martens-Lobenhoffer J; Knitsch W; Scherneck S; Welte T; Kielstein JT J Antimicrob Chemother; 2019 Apr; 74(4):997-1002. PubMed ID: 30624668 [TBL] [Abstract][Full Text] [Related]
6. Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome. Ram K; Sheikh S; Bhati RK; Tripathi CD; Suri JC; Meshram GG Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):128-140. PubMed ID: 33245629 [TBL] [Abstract][Full Text] [Related]
7. Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections. Durante-Mangoni E; Andini R; Signoriello S; Cavezza G; Murino P; Buono S; De Cristofaro M; Taglialatela C; Bassetti M; Malacarne P; Petrosillo N; Corcione A; Viscoli C; Utili R; Gallo C Clin Microbiol Infect; 2016 Dec; 22(12):984-989. PubMed ID: 27545697 [TBL] [Abstract][Full Text] [Related]
8. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000 [TBL] [Abstract][Full Text] [Related]
9. Colistin nephrotoxicity in critically ill patients after implementation of a new dosing strategy. Ozel AS; Ergönül Ö; Korten V J Infect Dev Ctries; 2019 Oct; 13(10):877-885. PubMed ID: 32084017 [TBL] [Abstract][Full Text] [Related]
10. Acute kidney injury following colistin treatment in critically-ill patients: may glucocorticoids protect? Heybeli C; Canaslan K; Oktan MA; Yıldız S; Arda HÜ; Çavdar C; Çelik A; Gökmen N; Cömert B J Chemother; 2021 Apr; 33(2):85-94. PubMed ID: 32500843 [TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Garonzik SM; Li J; Thamlikitkul V; Paterson DL; Shoham S; Jacob J; Silveira FP; Forrest A; Nation RL Antimicrob Agents Chemother; 2011 Jul; 55(7):3284-94. PubMed ID: 21555763 [TBL] [Abstract][Full Text] [Related]
12. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin. Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560 [TBL] [Abstract][Full Text] [Related]
13. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Rocco M; Montini L; Alessandri E; Venditti M; Laderchi A; De Pascale G; Raponi G; Vitale M; Pietropaoli P; Antonelli M Crit Care; 2013 Aug; 17(4):R174. PubMed ID: 23945197 [TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis. Jacobs M; Grégoire N; Mégarbane B; Gobin P; Balayn D; Marchand S; Mimoz O; Couet W Antimicrob Agents Chemother; 2016 Jan; 60(3):1788-93. PubMed ID: 26729492 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of a Colistin Loading Dose, High-Dose Maintenance Regimen in Critically Ill Patients With Multidrug-Resistant Gram-Negative Pneumonia. Elefritz JL; Bauer KA; Jones C; Mangino JE; Porter K; Murphy CV J Intensive Care Med; 2017 Sep; 32(8):487-493. PubMed ID: 27139010 [TBL] [Abstract][Full Text] [Related]
17. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. Grégoire N; Mimoz O; Mégarbane B; Comets E; Chatelier D; Lasocki S; Gauzit R; Balayn D; Gobin P; Marchand S; Couet W Antimicrob Agents Chemother; 2014 Dec; 58(12):7324-30. PubMed ID: 25267662 [TBL] [Abstract][Full Text] [Related]
18. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Boisson M; Jacobs M; Grégoire N; Gobin P; Marchand S; Couet W; Mimoz O Antimicrob Agents Chemother; 2014 Dec; 58(12):7331-9. PubMed ID: 25267660 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill Neonates. Nakwan N; Usaha S; Chokephaibulkit K; Villani P; Regazzi M; Imberti R Pediatr Infect Dis J; 2016 Nov; 35(11):1211-1214. PubMed ID: 27276179 [TBL] [Abstract][Full Text] [Related]
20. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Ko Hj; Jeon Mh; Choo Ej; Lee Ej; Kim Th; Jun JB; Gil HW Nephron Clin Pract; 2011; 117(3):c284-8. PubMed ID: 20847571 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]